Reuters logo
BRIEF-Eli Lilly updates on Jardiance tablets
September 12, 2017 / 11:10 AM / 13 days ago

BRIEF-Eli Lilly updates on Jardiance tablets

Sept 12 (Reuters) - Eli Lilly And Co:

* Jardiance® (Empagliflozin) tablets reduced risk of cardiovascular death in people with type 2 diabetes and established cardiovascular disease independent of background blood sugar control

* Eli Lilly and Co - ‍ Jardiance also reduced risk of cardiovascular death compared to placebo regardless of background metformin or sulfonylurea use​

* Eli Lilly and co -‍overall safety profile of Jardiance in EMPA-REG outcome was consistent with previous studies of Jardiance, current label information​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below